News

"This is a great result for the Mitchell family and all the other victims of AbbVie's fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears

NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory

The deal will help MTPC grow its product pipeline in the central nervous system disease area. The company intends to offer patients with innovative drugs for unmet medical needs.  

The grant from CIRM is a significant endorsement of the potential for Brainstorm's novel approach to treat ALS using adult stem cells. CIRM is the World's Largest Institution

In a study released today in JCI Insight, Feinstein Institute researchers found that the FDA-approved Alzheimer’s drug “galantamine” cut key markers of inflammation – a hallmark of metabolic

IBM scientists and the University of Alberta in Edmonton, Canada, have published new data in Nature's partner journal. The research was on computational psychiatry which uses AI to

The FDA approval marks the first subcutaneous self-injection treatment option for patients with SLE, the most common form of lupus – a chronic, incurable autoimmune disease producing autoantibodies

The trial will evaluate the efficacy and safety of itacitinib, Incyte’s novel, potent, and selective JAK1 inhibitor, in combination with corticosteroids compared to placebo plus corticosteroids in patients

LUSDUNA Nexvue is being developed by Merck with funding from Samsung Bioepis. With the tentative approval, LUSDUNA Nexvue has met all required regulatory standards for follow-on biologics of